- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01187849
Metformin to Prevent Metabolic Complications in Glucocorticoid Excess
April 27, 2016 updated by: University Hospital, Basel, Switzerland
The purpose of this study is to evaluate if a treatment with metformin compared to placebo reduces metabolic side-effects in patients with glucocorticoid treatment over three months time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Basel-Stadt
-
Basel, Basel-Stadt, Switzerland, 4031
- University Hospital Basel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Glucocorticoid treatment for ≥ 3 months with a prednisone dose of ≥ 7.5mg/d or equivalent glucocorticoid
Exclusion Criteria:
- Refusal of informed consent
- Prior therapy with metformin during the last 6 month
- Preexisting diabetes
- Pregnancy or current malignancy
- Renal insufficiency with a creatinine clearance lower than 30ml/min
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Volunteers will be given Metformin or placebo for 1 month, once daily
|
|
Active Comparator: Metformin
|
Volunteers will be given Metformin or placebo for 1 month, once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
2 hours glucose level after a standardized 75g oral glucose tolerance test (OGTT)
Time Frame: 0 months, 3 months
|
0 months, 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
homeostasis model assessment (HOMA)-index
Time Frame: 0 months, 3 months
|
0 months, 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mirjam Christ-Crain, MD, Prof., University Hospital, Basel, Switzerland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 23, 2010
First Submitted That Met QC Criteria
August 23, 2010
First Posted (Estimate)
August 24, 2010
Study Record Updates
Last Update Posted (Estimate)
April 28, 2016
Last Update Submitted That Met QC Criteria
April 27, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKBB 245/09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Glucocorticoid Treatment
-
Persei VivariumEffice Servicios Para la Investigacion S.L.CompletedCancer Patients With Outpatient TreatmentSpain
-
Elizabeth DudnikRecruitingPatients With Advanced Treatment Naive LCNECIsrael
-
Prince of Songkla UniversityUnknownPatients With Urosepis and Received Ertapenem for TreatmentThailand
-
Fujian Cancer HospitalNot yet recruitingPatients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
-
Yonsei UniversityWithdrawnPatients in the Treatment of Subjects With All-comer Who Are to Undergo PCI
-
Yonsei UniversityCompletedPatients on Treatment With Systemic SteroidsSouth Korea
-
Konya Necmettin Erbakan ÜniversitesiActive, not recruitingEvaluation of Speech Characteristics Following MARPE Treatment in Patients With Maxillary Transverse DeficiencyTurkey (Türkiye)
-
University of PennsylvaniaLeonard Davis InstituteCompletedDecision Making About Life-sustaining Treatment in Patients With Serious Cardiac, Respiratory and Oncological Conditions Likely to Limit Life ExpectancyUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment LinesItaly
-
Meir Medical CenterUnknownPatients With Normal ECG | Patients With Pathological ECGIsrael
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Aspargo Labs, IncNot yet recruitingHealthy Volunteers
-
Aspargo Labs, IncNot yet recruitingHealthy Volunteers
-
Charles University, Czech RepublicCompleted
-
Aspargo Labs, IncNot yet recruiting
-
German Diabetes CenterYale UniversityActive, not recruiting
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina